nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—systemic scleroderma	0.396	1	CiPCiCtD
Pemetrexed—Methotrexate—systemic scleroderma	0.257	1	CrCtD
Pemetrexed—ATIC—Methotrexate—systemic scleroderma	0.0502	0.377	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—systemic scleroderma	0.0399	0.299	CbGbCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—systemic scleroderma	0.034	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—systemic scleroderma	0.034	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—systemic scleroderma	0.034	0.2	CrCrCtD
Pemetrexed—Pralatrexate—Methotrexate—systemic scleroderma	0.034	0.2	CrCrCtD
Pemetrexed—Raltitrexed—Methotrexate—systemic scleroderma	0.034	0.2	CrCrCtD
Pemetrexed—DHFR—Methotrexate—systemic scleroderma	0.0255	0.191	CbGbCtD
Pemetrexed—TYMS—Methotrexate—systemic scleroderma	0.0178	0.133	CbGbCtD
Pemetrexed—GART—digestive system—systemic scleroderma	0.000544	0.0622	CbGeAlD
Pemetrexed—GART—tendon—systemic scleroderma	0.000518	0.0592	CbGeAlD
Pemetrexed—ATIC—connective tissue—systemic scleroderma	0.000511	0.0585	CbGeAlD
Pemetrexed—ATIC—smooth muscle tissue—systemic scleroderma	0.000468	0.0535	CbGeAlD
Pemetrexed—ATIC—skin of body—systemic scleroderma	0.000462	0.0528	CbGeAlD
Pemetrexed—GART—lung—systemic scleroderma	0.000454	0.052	CbGeAlD
Pemetrexed—SLC46A1—digestive system—systemic scleroderma	0.000441	0.0505	CbGeAlD
Pemetrexed—SLC46A1—tendon—systemic scleroderma	0.00042	0.0481	CbGeAlD
Pemetrexed—ATIC—digestive system—systemic scleroderma	0.000369	0.0423	CbGeAlD
Pemetrexed—TYMS—connective tissue—systemic scleroderma	0.000347	0.0397	CbGeAlD
Pemetrexed—DHFR—connective tissue—systemic scleroderma	0.000343	0.0393	CbGeAlD
Pemetrexed—TYMS—smooth muscle tissue—systemic scleroderma	0.000317	0.0363	CbGeAlD
Pemetrexed—TYMS—skin of body—systemic scleroderma	0.000313	0.0358	CbGeAlD
Pemetrexed—SLC29A1—connective tissue—systemic scleroderma	0.000311	0.0356	CbGeAlD
Pemetrexed—ATIC—lung—systemic scleroderma	0.000308	0.0353	CbGeAlD
Pemetrexed—TYMS—digestive system—systemic scleroderma	0.00025	0.0287	CbGeAlD
Pemetrexed—DHFR—digestive system—systemic scleroderma	0.000248	0.0284	CbGeAlD
Pemetrexed—TYMS—tendon—systemic scleroderma	0.000238	0.0273	CbGeAlD
Pemetrexed—DHFR—tendon—systemic scleroderma	0.000236	0.027	CbGeAlD
Pemetrexed—SLC29A1—digestive system—systemic scleroderma	0.000225	0.0257	CbGeAlD
Pemetrexed—DCK—digestive system—systemic scleroderma	0.000215	0.0245	CbGeAlD
Pemetrexed—SLC29A1—tendon—systemic scleroderma	0.000214	0.0245	CbGeAlD
Pemetrexed—TYMS—lung—systemic scleroderma	0.000209	0.0239	CbGeAlD
Pemetrexed—DHFR—lung—systemic scleroderma	0.000207	0.0237	CbGeAlD
Pemetrexed—DCK—tendon—systemic scleroderma	0.000204	0.0234	CbGeAlD
Pemetrexed—SLC29A1—lung—systemic scleroderma	0.000188	0.0215	CbGeAlD
Pemetrexed—DCK—lung—systemic scleroderma	0.000179	0.0205	CbGeAlD
Pemetrexed—DCK—Desoximetasone—Mometasone—systemic scleroderma	7.58e-05	0.1	CbGdCrCtD
Pemetrexed—DCK—Diflorasone—Mometasone—systemic scleroderma	7.36e-05	0.0971	CbGdCrCtD
Pemetrexed—TYMS—Clobetasol propionate—Mometasone—systemic scleroderma	6.16e-05	0.0812	CbGdCrCtD
Pemetrexed—TYMS—Flunisolide—Mometasone—systemic scleroderma	6.08e-05	0.0802	CbGdCrCtD
Pemetrexed—TYMS—Triamcinolone—Mometasone—systemic scleroderma	6.01e-05	0.0794	CbGdCrCtD
Pemetrexed—TYMS—Fluticasone Propionate—Mometasone—systemic scleroderma	5.86e-05	0.0774	CbGdCrCtD
Pemetrexed—TYMS—Diflorasone—Mometasone—systemic scleroderma	5.54e-05	0.0731	CbGdCrCtD
Pemetrexed—TYMS—Budesonide—Mometasone—systemic scleroderma	4.86e-05	0.0641	CbGdCrCtD
Pemetrexed—Body temperature increased—Captopril—systemic scleroderma	4.37e-05	0.00126	CcSEcCtD
Pemetrexed—Oedema—Mycophenolic acid—systemic scleroderma	4.34e-05	0.00126	CcSEcCtD
Pemetrexed—Anorexia—Leflunomide—systemic scleroderma	4.34e-05	0.00126	CcSEcCtD
Pemetrexed—Nausea—Pentoxifylline—systemic scleroderma	4.33e-05	0.00125	CcSEcCtD
Pemetrexed—Infection—Mycophenolic acid—systemic scleroderma	4.32e-05	0.00125	CcSEcCtD
Pemetrexed—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.00125	CcSEcCtD
Pemetrexed—Diarrhoea—Mometasone—systemic scleroderma	4.3e-05	0.00125	CcSEcCtD
Pemetrexed—Syncope—Lisinopril—systemic scleroderma	4.3e-05	0.00124	CcSEcCtD
Pemetrexed—Leukopenia—Lisinopril—systemic scleroderma	4.29e-05	0.00124	CcSEcCtD
Pemetrexed—Renal failure acute—Methotrexate—systemic scleroderma	4.28e-05	0.00124	CcSEcCtD
Pemetrexed—Shock—Mycophenolic acid—systemic scleroderma	4.27e-05	0.00124	CcSEcCtD
Pemetrexed—Alopecia—Mycophenolate mofetil—systemic scleroderma	4.26e-05	0.00123	CcSEcCtD
Pemetrexed—Nervous system disorder—Mycophenolic acid—systemic scleroderma	4.26e-05	0.00123	CcSEcCtD
Pemetrexed—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	4.25e-05	0.00123	CcSEcCtD
Pemetrexed—Skin disorder—Mycophenolic acid—systemic scleroderma	4.22e-05	0.00122	CcSEcCtD
Pemetrexed—Loss of consciousness—Lisinopril—systemic scleroderma	4.21e-05	0.00122	CcSEcCtD
Pemetrexed—Malnutrition—Mycophenolate mofetil—systemic scleroderma	4.2e-05	0.00122	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Prednisone—systemic scleroderma	4.17e-05	0.00121	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Azathioprine—systemic scleroderma	4.16e-05	0.0012	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	4.15e-05	0.0012	CcSEcCtD
Pemetrexed—Anorexia—Mycophenolic acid—systemic scleroderma	4.14e-05	0.0012	CcSEcCtD
Pemetrexed—DCK—Desoximetasone—Prednisone—systemic scleroderma	4.13e-05	0.0546	CbGdCrCtD
Pemetrexed—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	4.11e-05	0.00119	CcSEcCtD
Pemetrexed—Arthralgia—Lisinopril—systemic scleroderma	4.08e-05	0.00118	CcSEcCtD
Pemetrexed—Myalgia—Lisinopril—systemic scleroderma	4.08e-05	0.00118	CcSEcCtD
Pemetrexed—Chest pain—Lisinopril—systemic scleroderma	4.08e-05	0.00118	CcSEcCtD
Pemetrexed—Dyspnoea—Leflunomide—systemic scleroderma	4.06e-05	0.00117	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	4.05e-05	0.00117	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Methotrexate—systemic scleroderma	4.03e-05	0.00117	CcSEcCtD
Pemetrexed—DCK—Diflorasone—Prednisone—systemic scleroderma	4.01e-05	0.053	CbGdCrCtD
Pemetrexed—Dyspepsia—Leflunomide—systemic scleroderma	4.01e-05	0.00116	CcSEcCtD
Pemetrexed—Pancreatitis—Prednisone—systemic scleroderma	4.01e-05	0.00116	CcSEcCtD
Pemetrexed—Vomiting—Mometasone—systemic scleroderma	4e-05	0.00116	CcSEcCtD
Pemetrexed—Rash—Mometasone—systemic scleroderma	3.97e-05	0.00115	CcSEcCtD
Pemetrexed—Asthenia—Captopril—systemic scleroderma	3.96e-05	0.00115	CcSEcCtD
Pemetrexed—Dermatitis—Mometasone—systemic scleroderma	3.96e-05	0.00115	CcSEcCtD
Pemetrexed—Decreased appetite—Leflunomide—systemic scleroderma	3.96e-05	0.00115	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	3.96e-05	0.00115	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Azathioprine—systemic scleroderma	3.94e-05	0.00114	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Leflunomide—systemic scleroderma	3.93e-05	0.00114	CcSEcCtD
Pemetrexed—Fatigue—Leflunomide—systemic scleroderma	3.93e-05	0.00114	CcSEcCtD
Pemetrexed—Oedema—Lisinopril—systemic scleroderma	3.91e-05	0.00113	CcSEcCtD
Pemetrexed—Anaphylactic shock—Lisinopril—systemic scleroderma	3.91e-05	0.00113	CcSEcCtD
Pemetrexed—Pruritus—Captopril—systemic scleroderma	3.91e-05	0.00113	CcSEcCtD
Pemetrexed—Pain—Leflunomide—systemic scleroderma	3.89e-05	0.00113	CcSEcCtD
Pemetrexed—Constipation—Leflunomide—systemic scleroderma	3.89e-05	0.00113	CcSEcCtD
Pemetrexed—Infection—Lisinopril—systemic scleroderma	3.89e-05	0.00112	CcSEcCtD
Pemetrexed—Anaemia—Mycophenolate mofetil—systemic scleroderma	3.88e-05	0.00112	CcSEcCtD
Pemetrexed—Dyspnoea—Mycophenolic acid—systemic scleroderma	3.87e-05	0.00112	CcSEcCtD
Pemetrexed—Shock—Lisinopril—systemic scleroderma	3.85e-05	0.00111	CcSEcCtD
Pemetrexed—Thrombocytopenia—Lisinopril—systemic scleroderma	3.83e-05	0.00111	CcSEcCtD
Pemetrexed—Dyspepsia—Mycophenolic acid—systemic scleroderma	3.82e-05	0.00111	CcSEcCtD
Pemetrexed—Neutropenia—Prednisone—systemic scleroderma	3.82e-05	0.00111	CcSEcCtD
Pemetrexed—Body temperature increased—Azathioprine—systemic scleroderma	3.81e-05	0.0011	CcSEcCtD
Pemetrexed—Abdominal pain—Azathioprine—systemic scleroderma	3.81e-05	0.0011	CcSEcCtD
Pemetrexed—Skin disorder—Lisinopril—systemic scleroderma	3.8e-05	0.0011	CcSEcCtD
Pemetrexed—Diarrhoea—Captopril—systemic scleroderma	3.78e-05	0.00109	CcSEcCtD
Pemetrexed—Decreased appetite—Mycophenolic acid—systemic scleroderma	3.78e-05	0.00109	CcSEcCtD
Pemetrexed—Syncope—Mycophenolate mofetil—systemic scleroderma	3.77e-05	0.00109	CcSEcCtD
Pemetrexed—Leukopenia—Mycophenolate mofetil—systemic scleroderma	3.76e-05	0.00109	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	3.75e-05	0.00109	CcSEcCtD
Pemetrexed—Fatigue—Mycophenolic acid—systemic scleroderma	3.75e-05	0.00108	CcSEcCtD
Pemetrexed—Mood swings—Methotrexate—systemic scleroderma	3.74e-05	0.00108	CcSEcCtD
Pemetrexed—Nausea—Mometasone—systemic scleroderma	3.74e-05	0.00108	CcSEcCtD
Pemetrexed—Anorexia—Lisinopril—systemic scleroderma	3.73e-05	0.00108	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Leflunomide—systemic scleroderma	3.72e-05	0.00108	CcSEcCtD
Pemetrexed—Pain—Mycophenolic acid—systemic scleroderma	3.71e-05	0.00107	CcSEcCtD
Pemetrexed—Constipation—Mycophenolic acid—systemic scleroderma	3.71e-05	0.00107	CcSEcCtD
Pemetrexed—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	3.69e-05	0.00107	CcSEcCtD
Pemetrexed—Dizziness—Captopril—systemic scleroderma	3.65e-05	0.00106	CcSEcCtD
Pemetrexed—Hypertension—Mycophenolate mofetil—systemic scleroderma	3.63e-05	0.00105	CcSEcCtD
Pemetrexed—Urticaria—Leflunomide—systemic scleroderma	3.62e-05	0.00105	CcSEcCtD
Pemetrexed—Abdominal pain—Leflunomide—systemic scleroderma	3.6e-05	0.00104	CcSEcCtD
Pemetrexed—Body temperature increased—Leflunomide—systemic scleroderma	3.6e-05	0.00104	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Prednisone—systemic scleroderma	3.59e-05	0.00104	CcSEcCtD
Pemetrexed—Arthralgia—Mycophenolate mofetil—systemic scleroderma	3.58e-05	0.00103	CcSEcCtD
Pemetrexed—Chest pain—Mycophenolate mofetil—systemic scleroderma	3.58e-05	0.00103	CcSEcCtD
Pemetrexed—Myalgia—Mycophenolate mofetil—systemic scleroderma	3.58e-05	0.00103	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Prednisone—systemic scleroderma	3.57e-05	0.00103	CcSEcCtD
Pemetrexed—Myocardial infarction—Prednisone—systemic scleroderma	3.57e-05	0.00103	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	3.56e-05	0.00103	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	3.56e-05	0.00103	CcSEcCtD
Pemetrexed—Hypersensitivity—Azathioprine—systemic scleroderma	3.55e-05	0.00103	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	3.55e-05	0.00103	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	3.55e-05	0.00103	CcSEcCtD
Pemetrexed—Vomiting—Captopril—systemic scleroderma	3.51e-05	0.00102	CcSEcCtD
Pemetrexed—Dyspnoea—Lisinopril—systemic scleroderma	3.49e-05	0.00101	CcSEcCtD
Pemetrexed—Rash—Captopril—systemic scleroderma	3.48e-05	0.00101	CcSEcCtD
Pemetrexed—Dermatitis—Captopril—systemic scleroderma	3.48e-05	0.00101	CcSEcCtD
Pemetrexed—Dyspepsia—Lisinopril—systemic scleroderma	3.44e-05	0.000997	CcSEcCtD
Pemetrexed—Body temperature increased—Mycophenolic acid—systemic scleroderma	3.43e-05	0.000994	CcSEcCtD
Pemetrexed—Abdominal pain—Mycophenolic acid—systemic scleroderma	3.43e-05	0.000994	CcSEcCtD
Pemetrexed—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	3.43e-05	0.000992	CcSEcCtD
Pemetrexed—Oedema—Mycophenolate mofetil—systemic scleroderma	3.43e-05	0.000992	CcSEcCtD
Pemetrexed—Infection—Mycophenolate mofetil—systemic scleroderma	3.41e-05	0.000985	CcSEcCtD
Pemetrexed—Decreased appetite—Lisinopril—systemic scleroderma	3.4e-05	0.000984	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Lisinopril—systemic scleroderma	3.38e-05	0.000977	CcSEcCtD
Pemetrexed—Fatigue—Lisinopril—systemic scleroderma	3.37e-05	0.000976	CcSEcCtD
Pemetrexed—Shock—Mycophenolate mofetil—systemic scleroderma	3.37e-05	0.000976	CcSEcCtD
Pemetrexed—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	3.36e-05	0.000973	CcSEcCtD
Pemetrexed—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	3.36e-05	0.000971	CcSEcCtD
Pemetrexed—TYMS—Clobetasol propionate—Prednisone—systemic scleroderma	3.36e-05	0.0443	CbGdCrCtD
Pemetrexed—Hypersensitivity—Leflunomide—systemic scleroderma	3.35e-05	0.000971	CcSEcCtD
Pemetrexed—Pancreatitis—Methotrexate—systemic scleroderma	3.35e-05	0.000969	CcSEcCtD
Pemetrexed—Pain—Lisinopril—systemic scleroderma	3.35e-05	0.000968	CcSEcCtD
Pemetrexed—Constipation—Lisinopril—systemic scleroderma	3.35e-05	0.000968	CcSEcCtD
Pemetrexed—Skin disorder—Mycophenolate mofetil—systemic scleroderma	3.33e-05	0.000963	CcSEcCtD
Pemetrexed—TYMS—Flunisolide—Prednisone—systemic scleroderma	3.31e-05	0.0437	CbGdCrCtD
Pemetrexed—Diarrhoea—Azathioprine—systemic scleroderma	3.3e-05	0.000955	CcSEcCtD
Pemetrexed—Nausea—Captopril—systemic scleroderma	3.28e-05	0.00095	CcSEcCtD
Pemetrexed—TYMS—Triamcinolone—Prednisone—systemic scleroderma	3.28e-05	0.0433	CbGdCrCtD
Pemetrexed—Anorexia—Mycophenolate mofetil—systemic scleroderma	3.27e-05	0.000945	CcSEcCtD
Pemetrexed—Asthenia—Leflunomide—systemic scleroderma	3.27e-05	0.000945	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—systemic scleroderma	3.24e-05	0.000938	CcSEcCtD
Pemetrexed—Pruritus—Leflunomide—systemic scleroderma	3.22e-05	0.000932	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Lisinopril—systemic scleroderma	3.2e-05	0.000926	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—systemic scleroderma	3.19e-05	0.000924	CcSEcCtD
Pemetrexed—Dizziness—Azathioprine—systemic scleroderma	3.19e-05	0.000923	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	3.12e-05	0.000904	CcSEcCtD
Pemetrexed—Asthenia—Mycophenolic acid—systemic scleroderma	3.12e-05	0.000902	CcSEcCtD
Pemetrexed—Diarrhoea—Leflunomide—systemic scleroderma	3.12e-05	0.000901	CcSEcCtD
Pemetrexed—Urticaria—Lisinopril—systemic scleroderma	3.11e-05	0.000899	CcSEcCtD
Pemetrexed—Abdominal pain—Lisinopril—systemic scleroderma	3.09e-05	0.000895	CcSEcCtD
Pemetrexed—Body temperature increased—Lisinopril—systemic scleroderma	3.09e-05	0.000895	CcSEcCtD
Pemetrexed—Pruritus—Mycophenolic acid—systemic scleroderma	3.07e-05	0.000889	CcSEcCtD
Pemetrexed—Vomiting—Azathioprine—systemic scleroderma	3.07e-05	0.000887	CcSEcCtD
Pemetrexed—Eye disorder—Prednisone—systemic scleroderma	3.06e-05	0.000884	CcSEcCtD
Pemetrexed—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	3.06e-05	0.000884	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—systemic scleroderma	3.05e-05	0.000881	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—systemic scleroderma	3.05e-05	0.000881	CcSEcCtD
Pemetrexed—Rash—Azathioprine—systemic scleroderma	3.04e-05	0.00088	CcSEcCtD
Pemetrexed—Dermatitis—Azathioprine—systemic scleroderma	3.04e-05	0.000879	CcSEcCtD
Pemetrexed—TYMS—Diflorasone—Prednisone—systemic scleroderma	3.02e-05	0.0399	CbGdCrCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	3.02e-05	0.000873	CcSEcCtD
Pemetrexed—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	3.02e-05	0.000873	CcSEcCtD
Pemetrexed—Dizziness—Leflunomide—systemic scleroderma	3.01e-05	0.000871	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—systemic scleroderma	2.99e-05	0.000866	CcSEcCtD
Pemetrexed—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	2.98e-05	0.000862	CcSEcCtD
Pemetrexed—Diarrhoea—Mycophenolic acid—systemic scleroderma	2.97e-05	0.00086	CcSEcCtD
Pemetrexed—Stomatitis—Methotrexate—systemic scleroderma	2.97e-05	0.000859	CcSEcCtD
Pemetrexed—Conjunctivitis—Methotrexate—systemic scleroderma	2.96e-05	0.000856	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	2.96e-05	0.000856	CcSEcCtD
Pemetrexed—Pain—Mycophenolate mofetil—systemic scleroderma	2.93e-05	0.000848	CcSEcCtD
Pemetrexed—Constipation—Mycophenolate mofetil—systemic scleroderma	2.93e-05	0.000848	CcSEcCtD
Pemetrexed—Arrhythmia—Prednisone—systemic scleroderma	2.92e-05	0.000845	CcSEcCtD
Pemetrexed—Vomiting—Leflunomide—systemic scleroderma	2.9e-05	0.000838	CcSEcCtD
Pemetrexed—Alopecia—Prednisone—systemic scleroderma	2.89e-05	0.000836	CcSEcCtD
Pemetrexed—Hypersensitivity—Lisinopril—systemic scleroderma	2.88e-05	0.000834	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Methotrexate—systemic scleroderma	2.88e-05	0.000833	CcSEcCtD
Pemetrexed—Dizziness—Mycophenolic acid—systemic scleroderma	2.87e-05	0.000831	CcSEcCtD
Pemetrexed—Rash—Leflunomide—systemic scleroderma	2.87e-05	0.000831	CcSEcCtD
Pemetrexed—Dermatitis—Leflunomide—systemic scleroderma	2.87e-05	0.00083	CcSEcCtD
Pemetrexed—Nausea—Azathioprine—systemic scleroderma	2.86e-05	0.000829	CcSEcCtD
Pemetrexed—Malnutrition—Prednisone—systemic scleroderma	2.85e-05	0.000824	CcSEcCtD
Pemetrexed—Erythema—Prednisone—systemic scleroderma	2.85e-05	0.000824	CcSEcCtD
Pemetrexed—Agranulocytosis—Methotrexate—systemic scleroderma	2.84e-05	0.000822	CcSEcCtD
Pemetrexed—Asthenia—Lisinopril—systemic scleroderma	2.81e-05	0.000812	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	2.8e-05	0.000811	CcSEcCtD
Pemetrexed—Pruritus—Lisinopril—systemic scleroderma	2.77e-05	0.000801	CcSEcCtD
Pemetrexed—Vomiting—Mycophenolic acid—systemic scleroderma	2.76e-05	0.000799	CcSEcCtD
Pemetrexed—Rash—Mycophenolic acid—systemic scleroderma	2.74e-05	0.000792	CcSEcCtD
Pemetrexed—Dermatitis—Mycophenolic acid—systemic scleroderma	2.74e-05	0.000792	CcSEcCtD
Pemetrexed—Hepatitis—Methotrexate—systemic scleroderma	2.73e-05	0.000791	CcSEcCtD
Pemetrexed—Urticaria—Mycophenolate mofetil—systemic scleroderma	2.72e-05	0.000788	CcSEcCtD
Pemetrexed—Pharyngitis—Methotrexate—systemic scleroderma	2.71e-05	0.000785	CcSEcCtD
Pemetrexed—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	2.71e-05	0.000784	CcSEcCtD
Pemetrexed—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	2.71e-05	0.000784	CcSEcCtD
Pemetrexed—Nausea—Leflunomide—systemic scleroderma	2.7e-05	0.000783	CcSEcCtD
Pemetrexed—Urinary tract disorder—Methotrexate—systemic scleroderma	2.7e-05	0.000781	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—systemic scleroderma	2.68e-05	0.000775	CcSEcCtD
Pemetrexed—Diarrhoea—Lisinopril—systemic scleroderma	2.68e-05	0.000775	CcSEcCtD
Pemetrexed—TYMS—Budesonide—Prednisone—systemic scleroderma	2.65e-05	0.035	CbGdCrCtD
Pemetrexed—Anaemia—Prednisone—systemic scleroderma	2.63e-05	0.000761	CcSEcCtD
Pemetrexed—Dizziness—Lisinopril—systemic scleroderma	2.59e-05	0.000749	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—systemic scleroderma	2.58e-05	0.000748	CcSEcCtD
Pemetrexed—Nausea—Mycophenolic acid—systemic scleroderma	2.58e-05	0.000747	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—systemic scleroderma	2.55e-05	0.000739	CcSEcCtD
Pemetrexed—Syncope—Prednisone—systemic scleroderma	2.55e-05	0.000739	CcSEcCtD
Pemetrexed—TYMS—Danazol—Prednisone—systemic scleroderma	2.54e-05	0.0335	CbGdCrCtD
Pemetrexed—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	2.53e-05	0.000731	CcSEcCtD
Pemetrexed—Loss of consciousness—Prednisone—systemic scleroderma	2.5e-05	0.000724	CcSEcCtD
Pemetrexed—Vomiting—Lisinopril—systemic scleroderma	2.49e-05	0.00072	CcSEcCtD
Pemetrexed—Rash—Lisinopril—systemic scleroderma	2.47e-05	0.000714	CcSEcCtD
Pemetrexed—Dermatitis—Lisinopril—systemic scleroderma	2.46e-05	0.000713	CcSEcCtD
Pemetrexed—Asthenia—Mycophenolate mofetil—systemic scleroderma	2.46e-05	0.000712	CcSEcCtD
Pemetrexed—Hypertension—Prednisone—systemic scleroderma	2.46e-05	0.000711	CcSEcCtD
Pemetrexed—Pruritus—Mycophenolate mofetil—systemic scleroderma	2.43e-05	0.000702	CcSEcCtD
Pemetrexed—Arthralgia—Prednisone—systemic scleroderma	2.42e-05	0.000701	CcSEcCtD
Pemetrexed—Myalgia—Prednisone—systemic scleroderma	2.42e-05	0.000701	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—systemic scleroderma	2.42e-05	0.000699	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	2.41e-05	0.000697	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—systemic scleroderma	2.38e-05	0.000689	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—systemic scleroderma	2.38e-05	0.000689	CcSEcCtD
Pemetrexed—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	2.35e-05	0.000679	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—systemic scleroderma	2.33e-05	0.000674	CcSEcCtD
Pemetrexed—Nausea—Lisinopril—systemic scleroderma	2.32e-05	0.000672	CcSEcCtD
Pemetrexed—Oedema—Prednisone—systemic scleroderma	2.32e-05	0.000672	CcSEcCtD
Pemetrexed—Anaphylactic shock—Prednisone—systemic scleroderma	2.32e-05	0.000672	CcSEcCtD
Pemetrexed—Infection—Prednisone—systemic scleroderma	2.31e-05	0.000668	CcSEcCtD
Pemetrexed—Shock—Prednisone—systemic scleroderma	2.29e-05	0.000661	CcSEcCtD
Pemetrexed—Nervous system disorder—Prednisone—systemic scleroderma	2.28e-05	0.000659	CcSEcCtD
Pemetrexed—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.27e-05	0.000656	CcSEcCtD
Pemetrexed—Skin disorder—Prednisone—systemic scleroderma	2.26e-05	0.000653	CcSEcCtD
Pemetrexed—Anorexia—Prednisone—systemic scleroderma	2.22e-05	0.000641	CcSEcCtD
Pemetrexed—Anaemia—Methotrexate—systemic scleroderma	2.2e-05	0.000636	CcSEcCtD
Pemetrexed—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.18e-05	0.000631	CcSEcCtD
Pemetrexed—Rash—Mycophenolate mofetil—systemic scleroderma	2.16e-05	0.000625	CcSEcCtD
Pemetrexed—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.16e-05	0.000625	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—systemic scleroderma	2.13e-05	0.000616	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.12e-05	0.000613	CcSEcCtD
Pemetrexed—Dyspepsia—Prednisone—systemic scleroderma	2.05e-05	0.000592	CcSEcCtD
Pemetrexed—Nausea—Mycophenolate mofetil—systemic scleroderma	2.04e-05	0.000589	CcSEcCtD
Pemetrexed—Chest pain—Methotrexate—systemic scleroderma	2.03e-05	0.000586	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—systemic scleroderma	2.03e-05	0.000586	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—systemic scleroderma	2.03e-05	0.000586	CcSEcCtD
Pemetrexed—Decreased appetite—Prednisone—systemic scleroderma	2.02e-05	0.000584	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.01e-05	0.000582	CcSEcCtD
Pemetrexed—Fatigue—Prednisone—systemic scleroderma	2e-05	0.00058	CcSEcCtD
Pemetrexed—Constipation—Prednisone—systemic scleroderma	1.99e-05	0.000575	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—systemic scleroderma	1.94e-05	0.000562	CcSEcCtD
Pemetrexed—Infection—Methotrexate—systemic scleroderma	1.93e-05	0.000558	CcSEcCtD
Pemetrexed—Nervous system disorder—Methotrexate—systemic scleroderma	1.9e-05	0.000551	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—systemic scleroderma	1.9e-05	0.00055	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Prednisone—systemic scleroderma	1.9e-05	0.00055	CcSEcCtD
Pemetrexed—Skin disorder—Methotrexate—systemic scleroderma	1.89e-05	0.000546	CcSEcCtD
Pemetrexed—Anorexia—Methotrexate—systemic scleroderma	1.85e-05	0.000536	CcSEcCtD
Pemetrexed—Urticaria—Prednisone—systemic scleroderma	1.85e-05	0.000534	CcSEcCtD
Pemetrexed—Abdominal pain—Prednisone—systemic scleroderma	1.84e-05	0.000532	CcSEcCtD
Pemetrexed—Body temperature increased—Prednisone—systemic scleroderma	1.84e-05	0.000532	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	1.77e-05	0.000512	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—systemic scleroderma	1.73e-05	0.000501	CcSEcCtD
Pemetrexed—Hypersensitivity—Prednisone—systemic scleroderma	1.71e-05	0.000495	CcSEcCtD
Pemetrexed—Dyspepsia—Methotrexate—systemic scleroderma	1.71e-05	0.000495	CcSEcCtD
Pemetrexed—Decreased appetite—Methotrexate—systemic scleroderma	1.69e-05	0.000488	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Methotrexate—systemic scleroderma	1.68e-05	0.000485	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—systemic scleroderma	1.67e-05	0.000484	CcSEcCtD
Pemetrexed—Asthenia—Prednisone—systemic scleroderma	1.67e-05	0.000482	CcSEcCtD
Pemetrexed—Pain—Methotrexate—systemic scleroderma	1.66e-05	0.000481	CcSEcCtD
Pemetrexed—Pruritus—Prednisone—systemic scleroderma	1.64e-05	0.000476	CcSEcCtD
Pemetrexed—Diarrhoea—Prednisone—systemic scleroderma	1.59e-05	0.00046	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—systemic scleroderma	1.59e-05	0.000459	CcSEcCtD
Pemetrexed—Urticaria—Methotrexate—systemic scleroderma	1.54e-05	0.000446	CcSEcCtD
Pemetrexed—Dizziness—Prednisone—systemic scleroderma	1.54e-05	0.000445	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—systemic scleroderma	1.54e-05	0.000444	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—systemic scleroderma	1.54e-05	0.000444	CcSEcCtD
Pemetrexed—Vomiting—Prednisone—systemic scleroderma	1.48e-05	0.000427	CcSEcCtD
Pemetrexed—Rash—Prednisone—systemic scleroderma	1.47e-05	0.000424	CcSEcCtD
Pemetrexed—Dermatitis—Prednisone—systemic scleroderma	1.46e-05	0.000424	CcSEcCtD
Pemetrexed—Hypersensitivity—Methotrexate—systemic scleroderma	1.43e-05	0.000414	CcSEcCtD
Pemetrexed—Asthenia—Methotrexate—systemic scleroderma	1.39e-05	0.000403	CcSEcCtD
Pemetrexed—Nausea—Prednisone—systemic scleroderma	1.38e-05	0.000399	CcSEcCtD
Pemetrexed—Pruritus—Methotrexate—systemic scleroderma	1.37e-05	0.000398	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—systemic scleroderma	1.33e-05	0.000384	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—systemic scleroderma	1.28e-05	0.000372	CcSEcCtD
Pemetrexed—Vomiting—Methotrexate—systemic scleroderma	1.23e-05	0.000357	CcSEcCtD
Pemetrexed—Rash—Methotrexate—systemic scleroderma	1.22e-05	0.000354	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—systemic scleroderma	1.22e-05	0.000354	CcSEcCtD
Pemetrexed—Nausea—Methotrexate—systemic scleroderma	1.15e-05	0.000334	CcSEcCtD
